Imatinib treatment for gastrointestinal stromal tumour (GIST)

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 42-50

  Lopes, Lisandro F ^a   Bacchi, Carlos E ^a  

^a Consultoria em Patologia ^*  (Brazil)

Author keywords

Gastrointestinal stromal tumour; GIST; Imatinib; KIT; Mutation; PDGFRA; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

DISEASE COURSE; DRUG ANTAGONISM; DRUG RESISTANCE; GASTROINTESTINAL STROMAL TUMOR; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 77951961590     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00983.x     Document Type: Review

References (102)

1. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology. 2006, 48:83-96.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130:1466-78.
3. Kindblom LG, Remotti HE, Aldenborg F. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998, 152:1259-69.
4. Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279:577-80.
5. Corless CL, McGreevey L, Haley A. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002, 160:1567-72.
6. Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003, 299:708-10.
7. Nilsson B, Bümming P, Meis-Kindblom JM. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005, 103:821-9.
8. Tryggvason G, Gíslason HG, Magnússon MK. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005, 117:289-93.
9. Mucciarini C, Rossi G, Bertolini F. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 2007, 7:230.
10. Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002, 33:459-65.
11. Prakash S, Sarran L, Socci N. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005, 27:179-87.
12. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005, 29:1373-81.
13. Lopes LF, Ojopi EB, Bacchi CE. Gastrointestinal stromal tumor in Brazil: clinicopathology, immunohistochemistry, and molecular genetics of 513 cases. Pathol Int. 2008, 58:344-52.
14. Miettinen M, Furlong M, Sarlomo-Rikala M. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001, 25:1121-33.
15. Miettinen M, Makhlouf H, Sobin LH. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006, 30:477-89.
16. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005, 29:52-68.
17. Miettinen M, Kopczynski J, Makhlouf HR. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol. 2003, 27:625-41.
18. Miettinen M, Sarlomo-Rikala M, Sobin LH. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000, 24:1339-52.
19. Miettinen M, Monihan JM, Sarlomo-Rikala M. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999, 23:1109-18.
20. Reith JD, Goldblum JR, Lyles RH. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000, 13:577-85.
21. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998, 11:728-34.
22. Medeiros F, Corless CL, Duensing A. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004, 28:889-94.
23. Mikhael AI, Bacchi CE, Zarbo RJ. CD34 expression in stromal tumors of the gastrointestinal tract. Appl Immunohistochem. 1994, 2:89-93.
24. West RB, Corless CL, Chen X. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004, 165:107-13.
25. Espinosa I, Lee CH, Kim MK. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008, 32:210-8.
26. Liegl B, Hornick JL, Corless CL. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009, 33:437-46.
27. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009, 33:1401-8.
28. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438:1-12.
29. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007, 51:509-14.
30. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23:70-83.
31. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39:1411-9.
32. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006, 17:x280-6.
33. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol. 2007, 18:x20-4.
34. Blay JY, Le Cesne A. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007, 18:ii27-9. ESMO Guidelines Working Group
35. Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag. 2008, 4:149-62.
36. Dirnhofer S, Leyvraz S. Current standards and progress in understanding and treatment of GIST. Swiss Med Wkly. 2009, 139:90-102.
37. Goodman VL, Rock EP, Dagher R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007, 13:1367-73.
38. Stenman G, Eriksson A, Claesson-Welsh L. Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene. Genes Chromosomes Cancer. 1989, 1:155-8.
39. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002, 38(Suppl 5):S3-10.
40. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004, 61:2924-31.
41. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004, 22:3813-25.
42. Rubin BP, Singer S, Tsao C. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61:8118-21.
43. Lux ML, Rubin BP, Biase TL. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000, 156:791-5.
44. Antonescu CR, Sommer G, Sarran L. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 2003, 9:3329-37.
45. Lasota J, Wozniak A, Sarlomo-Rikala M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol. 2000, 157:1091-5.
46. Hirota S, Nishida T, Isozaki K. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol. 2001, 193:505-10.
47. Kinoshita K, Isozaki K, Hirota S. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol. 2003, 18:147-51.
48. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53:245-66.
49. Corless CL, Schroeder A, Griffith D. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005, 23:5357-64.
50. Hirota S, Ohashi A, Nishida T. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003, 125:660-7.
51. Wasag B, Debiec-Rychter M, Pauwels P. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol. 2004, 17:889-94.
52. Debiec-Rychter M, Wasag B, Stul M. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol. 2004, 202:430-8.
53. Sakurai S, Hasegawa T, Sakuma Y. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol. 2004, 35:1223-30.
54. Tzen CY, Mau BL. Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol. 2005, 11:1052-5.
55. Wardelmann E, Hrychyk A, Merkelbach-Bruse S. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn. 2004, 6:197-204.
56. Duensing A, Joseph NE, Medeiros F. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004, 64:5127-31.
57. Agaram NP, Wong GC, Guo T. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008, 47:853-9.
58. Demetri GD, Benjamin RS, Blanke CD. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007, 5:S1-29.
59. Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347:472-80.
60. Tuveson DA, Willis NA, Jacks T. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001, 20:5054-8.
61. Dagher R, Cohen M, Williams G. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002, 8:3034-8.
62. Druker BJ, Tamura S, Buchdunger E. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2:561-6.
63. Heinrich MC, Griffith DJ, Druker BJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000, 96:925-32.
64. van Oosterom AT, Judson I, Verweij J. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001, 358:1421-3.
65. Blay JY, Le Cesne A, Ray-Coquard I. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007, 25:1107-13.
66. Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344:1052-6.
67. Andtbacka RH, Ng CS, Scaife CL. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007, 14:14-24.
68. DeMatteo RP, Maki RG, Singer S. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007, 245:347-52.
69. Gronchi A, Fiore M, Miselli F. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007, 245:341-6.
70. Haller F, Detken S, Schulten HJ. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007, 14:526-32.
71. Loughrey MB, Mitchell C, Mann GB. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol. 2005, 58:779-81.
72. Shah JN, Sun W, Seethala RR. Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc. 2005, 61:625-7.
73. von Mehren M. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Curr Opin Oncol. 2008, 20:428-32.
74. Nilsson B, Sjölund K, Kindblom LG. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer. 2007, 96:1656-8.
75. Dematteo RP, Ballman KV, Antonescu CR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373:1097-104.
76. Heinrich MC, Corless CL, Demetri GD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21:4342-9.
77. Debiec-Rychter M, Sciot R, Le Cesne A. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006, 42:1093-103.
78. Chen LL, Trent JC, Wu EF. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004, 64:5913-9.
79. Debiec-Rychter M, Cools J, Dumez H. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005, 128:270-9.
80. Tamborini E, Bonadiman L, Greco A. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004, 127:294-9.
81. Heinrich MC, Corless CL, Blanke CD. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006, 24:4764-74.
82. Miselli FC, Casieri P, Negri T. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res. 2007, 13:2369-77.
83. Antonescu CR, Besmer P, Guo T. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005, 11:4182-90.
84. Wardelmann E, Merkelbach-Bruse S, Pauls K. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006, 12:1743-9.
85. Bauer S, Duensing A, Demetri GD. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007, 26:7560-8.
86. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006, 6(Suppl 1):S30-4.
87. Abrams TJ, Lee LB, Murray LJ. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003, 2:471-8.
88. Mendel DB, Laird AD, Xin X. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003, 9:327-37.
89. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007, 25:884-96.
90. Demetri GD, van Oosterom AT, Garrett CR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368:1329-38.
91. George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep. 2007, 9:323-7.
92. Heinrich MC, Maki RG, Corless CL. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008, 26:5352-9.
93. Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep. 2008, 10:344-9.
94. Montemurro M, Schöffski P, Reichardt P. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009, 45:2293-7.
95. Demetri GD, Casali PG, Blay JY. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009, 15:5910-6.
96. Schittenhelm MM, Shiraga S, Schroeder A. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006, 66:473-81.
97. Dewaele B, Wasag B, Cools J. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res. 2008, 14:5749-58.
98. Guo T, Agaram NP, Wong GC. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007, 13:4874-81.
99. Soria JC, Massard C, Magné N. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer. 2009, 45:2333-41.
100. Joensuu H, De Braud F, Coco P. Phase II, open-label study of PTK787/ ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol. 2008, 19:173-7.
101. Rosen LS, Kurzrock R, Mulay M. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007, 25:2369-76.
102. Stamatakos M, Douzinas E, Stefanaki C. Gastrointestinal stromal tumor. World J Surg Oncol. 2009, 7:61.